Additionally, chromosomal analysis during the preimplantation stage by using Fluorescent In-situ Hybridization (FISH) has the potential to reduce the number of trisomic and monosomic pregnancies (e.g. Down’s syndrome), increase the pregnancy rates in women over age 40, and reduce embryo loss during pregnancy.
In a recent review of PGD around the world, the most common reasons for referral for the procedure was a suspected gene for cystic fibrosis, Duchenne’s or Becker’s muscular dystrophy, myotonic dystrophy, hemophilia, or Huntington’s disease. In these cases, most patients had affected children and decided to pursue PGD prior to attempting another pregnancy. Out of 70 cases, only a single (1.4%) misreported diagnosis occurred that was diagnosed by amniocentesis.
We are honored to be able to offer these advanced reproductive technologies that offer so much hope to our patients.